Literature DB >> 11074560

Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His.

V A Pullarkat1, S T Pullarkat, D C Calverley, R K Brynes.   

Abstract

Mast cell disease (MCD), a proliferation of mast cells (MC), is occasionally associated with hematologic malignancies. Neoplastic MC have activating c-kit mutations. c-kit is a receptor tyrosine kinase required for the development, proliferation, and survival of MC. Interaction of c-kit with its ligand stem cell factor induces dimerization, receptor phosphorylation, and signal transduction. The most common c-kit mutation detected in neoplastic MCD is Asp816Val, which results in ligand-independent autophosphorylation of the receptor leading to MC proliferation. We describe the rare occurrence of MCD associated with acute myeloid leukemia, report a novel c-kit mutation Asp816 His, and discuss the pathogenesis of MCD associated with hematologic malignancies. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074560     DOI: 10.1002/1096-8652(200012)65:4<307::aid-ajh10>3.0.co;2-f

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  "Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis.

Authors:  K Sotlar; W Saeger; F Stellmacher; J Stahmer; S Jäckle; P Valent; H-P Horny
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation.

Authors:  Hirokatsu Yanagihori; Noritaka Oyama; Koichiro Nakamura; Fumio Kaneko
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

Review 3.  Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.

Authors:  Oscar González-López; Javier I Muñoz-González; Alberto Orfao; Iván Álvarez-Twose; Andrés C García-Montero
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

4.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 5.  Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature.

Authors:  H-W Bernd; K Sotlar; J Lorenzen; R Osieka; U Fabry; P Valent; H-P Horny
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

6.  Systemic mastocytosis with acute myelomonocytic leukemia: a case report.

Authors:  Rakhee Kar; Seema Rao; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2009-01-11       Impact factor: 0.900

7.  Regulation of normal and neoplastic human mast cell development in mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

Review 8.  Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.

Authors:  Hengning Ke; Julhash U Kazi; Hui Zhao; Jianmin Sun
Journal:  Cell Biosci       Date:  2016-10-18       Impact factor: 7.133

Review 9.  Targeted Treatment Options in Mastocytosis.

Authors:  Mélanie Vaes; Fleur Samantha Benghiat; Olivier Hermine
Journal:  Front Med (Lausanne)       Date:  2017-07-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.